Udvalget for Humanmedicinske Lægemidler (CHMP) konkluderede, at fordelene ved Zonegran opve - jer risiciene som tillægsbehandling hos voksne patienter med partielle anfald med eller uden sekundær generalisering.
The Committee for Medicinal Products for Human Use (CHMP) decided that Zonegran’ s benefits are greater than its risks as adjunctive therapy in the treatment of adult patients with partial onset seizures, with or without secondary generalisation.